Manipulation of inflammation modulates hyperlipidemia in apolipoprotein E-deficient mice: A possible role for interleukin-6

Cytokine

Volumn 34, Issue 3-4, 2006, Pages 224-232

  Tous, Mònica ^a   Ribas, Vicent ^b   Escolà Gil, Joan Carles ^b   Blanco Vaca, Francisco ^b   Calpe Berdiel, Laura ^b   Coll, Blai ^a   Ferré, Natàlia ^a   Alonso Villaverde, Carlos ^a   Rull, Anna ^a   Camps, Jordi ^a   Joven, Jorge ^a  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Arteriosclerosis; Cholesterol; Dexamethasone; Inflammation; Interleukin 6

Indexed keywords

APOLIPOPROTEIN E; CORTICOSTEROID; DEXAMETHASONE; INTERLEUKIN 6; LIPID; LIPOPROTEIN; RECOMBINANT INTERLEUKIN 6; TRIACYLGLYCEROL; TURPENTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CARDIOTOXICITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG MECHANISM; HYPERLIPIDEMIA; IMMUNOCHEMISTRY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOPHARMACOLOGY; INFLAMMATION; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

RODENTIA;

EID: 33745833668     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2006.05.007     Document Type: Article

References (52)

1. Libby P., and Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116 Suppl. 6A (2004) 9S-16S
2. Rosenson R.S. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. Am J Cardiovasc Drugs 1 (2001) 411-420
3. Libby P. Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis and stabilization. Am J Cardiol 86 (2000) 3-8
4. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., and Hennekens C.H. Inflammation, aspirin and the risks of cardiovascular disease in apparently healthy men. N Engl J Med 336 (1997) 973-979
5. Tous M., Ribas V., Ferré N., Escolà-Gil J.C., Blanco-Vaca F., Alonso-Villaverde C., et al. Turpentine-induced inflammation reduces the hepatic expresión of the multiple drug resistance gene, the plasma colesterol concentration and the development of atherosclerosis in apolipoprotein E deficient mice. Biochim Biophys Acta 1733 (2005) 192-198
6. Paul A., Calleja L., Camps J., Osada J., Vilella E., Ferre N., et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci 68 (2000) 457-465
7. Cyrus T., Sung S., Zhao L., Funk C.D., Tang S., and Praticò D. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 106 (2002) 1282-1287
8. Reis E.D., Roque M., Dansky H., Fallon J.T., Badimon J.J., Cordon-Cardo C., et al. Sulindac inhibits neointimal formation after arterial injury in wild-type and Apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 23 (2000) 12764-12769
9. Cayatte A.J., Du Y., Oliver-Krasinski J., Lavielle G., Verbeuren T.J., and Cohen R.A. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in Apo E-deficient mice. Arterioscler Thromb Vasc Biol 20 (2000) 1724-1728
10. Praticò D., Tillmann C., Zhang Z.B., Li H., and FitzGerald G.A. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low-density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98 (2001) 3358-3363
11. Tous M., Ferré N., Vilella E., Riu F., Camps J., and Joven J. Aspirin attenuates the initiation but not the progression of atherosclerosis in apolipoprotein E-deficient mice fed a high-fat, high-cholesterol diet. Basic Clin Pharmacol Toxicol 95 (2004) 15-19
12. Giugliano G., Giugliano R., Gibson C.M., and Kuntz R.E. Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol 91 (2003) 1055-1059
13. Patti G., Pasceri V., Carminati P., D'Ambrosio A., Carcagni A., and di Sciascio G. Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol 95 (2005) 502-505
14. Friedman M., Byers S., and St George S. Cortisone and experimental atherosclerosis; effects upon administration. Arch Pathol 77 (1964) 142-158
15. Bailey M., and Butler J. Anti-inflammatory drugs in experimental atherosclerosis. I relative potencies for inhibiting plaque formation. Atherosclerosis 17 (1973) 515-522
16. Makheja A.N., Bloom S., Muesing R., Simon T., and Bailey J.M. Anti-inflammatory drugs in experimental atherosclerosis. Spontaneous atherosclerosis in WHHL rabbits and inhibition by cortisone acetate. Atherosclerosis 76 (1989) 155-161
17. Asai K., Funaki C., Hayashi T., Yamada K., Naito M., Kuzuya M., et al. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb 13 (1993) 892-899
18. Escola-Gil J.C., Julve J., Marzal-Casacuberta A., Ordonez-Llanos J., Gonzalez-Sastre F., and Blanco-Vaca F. Expression of human apolipoprotein A-II in apolipoprotein E-deficient mice induces features of familial combined hyperlipidemia. J Lipid Res 41 (2000) 1328-1338
19. Vilella E., Joven J., Fernandez M., Vilaro S., Brunzell J.D., Olivecrona T., et al. Lipoprotein lipase in human plasma is mainly inactive and associated with cholesterol-rich lipoproteins. J Lipid Res 34 (1993) 1555-1564
20. Julve J., Escola-Gil J.C., Marzal-Casacuberta A., Ordonez-Llanos J., Gonzalez-Sastre F., and Blanco-Vaca F. Increased production of very-low-density lipoproteins in transgenic mice overexpressing human apolipoprotein A-II and fed with a high-fat diet. Biochim Biophys Acta 1488 (2000) 233-244
21. Zhang S.H., Reddick R.L., Piedrahita J.A., and Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258 (1992) 468-471
22. Paigen B., Morrow A., Holmes P.A., Mitchell D., and Williams R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68 (1987) 231-240
23. Calpe-Berdiel L., Escola-Gil J.C., Ribas V., Navarro-Sastre A., Garces-Garces J., and Blanco-Vaca F. Changes in intestinal and liver global gene expression in response to a phytosterol-enriched diet. Atherosclerosis 181 (2005) 75-85
24. Rotllan N., Ribas V., Calpe-Berdiel L., Martin-Campos J.M., Blanco-Vaca F., and Escola-Gil J.C. Overexpression of human apolipoprotein A-II in transgenic mice does not impair macrophage-specific reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 25 (2005) 128-132
25. Jousilahti P., Vartiainen E., Tuomilehto J., and Puska P. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 348 (1996) 567-572
26. Hartmann G., Kim H., and Piquette-Miller M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int Immunopharmacol 1 (2001) 189-199
27. Nashel D.J. Is atherosclerosis a complication of long-term corticosteroid treatment?. Am J Med 80 (1986) 925-929
28. Cheng W., Kvilekval K.V., and Abumrad N.A. Dexamethasone enhances accumulation of cholesteryl esters by human macrophages. Am J Physiol 269 (1995) 642-648
29. Yang L., Yang J.B., Chen J., Yu G.Y., Zhou P., Lei L., et al. Enhancement of human ACAT1 gene expression to promote the macrophage-derived foam cell formation by dexamethasone. Cell Res 14 (2004) 315-323
30. Chono S., Tauchi Y., Deguchi Y., and Morimoto K. Efficient drug delivery to atherosclerotic lesions and the antiatherosclerotic effect by dexamethasone incorporated into liposomes in atherogenic mice. J Drug Target 13 (2005) 267-276
31. Bernal-Mizrachi C., Weng S., Feng C., Finck B.N., Knutsen R.H., Leone T.C., et al. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 9 (2003) 1069-1075
32. Dolinsky V.W., Douglas D.N., Lehner R., and Vance D.E. Regulation of the enzymes of hepatic microsomal triacylglycerol lipolysis and re-esterification by the glucocorticoid dexamethasone. Biochem J 378 (2004) 967-974
33. Wang C.N., McLeod R.S., Yao Z., and Brindley D.N. Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol 15 (1995) 1481-1491
34. Wilson M.D., and Rudel L.L. Review of cholesterol absorption with emphasis on dietary and biliary cholesterol. J Lipid Res 35 (1994) 943-955
35. Turley S.D. Cholesterol metabolism and therapeutic targets: rationale for targeting multiple metabolic pathways. Clin Cardiol 6 Suppl 3 (2004) 16-21
36. Lee G., and Piquette-Miller M. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J Pharm Sci 92 (2003) 2152-2163
37. Voshol P.J., Havinga R., Wolters H., Ottenhoff R., Princen H.M., Oude Elferink R.P., et al. Reduced plasma cholesterol and increased faecal sterol loss in multidrug resistance gene 2 P-glycoprotein-deficient mice. Gastroenterology 114 (1998) 1024-1034
38. Piquette-Miller M., Pak A., Kim H., Anari R., and Shahzamani A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm Res 15 (1998) 706-711
39. bin Ali A., Zhang Q., Lim Y.K., Fang D., Retnam L., and Lim S.K. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Free Radic Biol Med 34 (2003) 824-829
40. Paoletti R., Gotto Jr. A.M., and Hajjar D.P. Inflammation in atherosclerosis and implications for therapy. Circulation 109 (2004) III20-III26
41. Kopf M., Baumann H., Freer G., Freudenberg M., Lamers M., Kishimoto T., et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368 (1994) 339-342
42. Xing Z., Gauldie J., Cox G., Baumann H., Jordana M., Lei X.F., et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 101 (1998) 311-320
43. Swolin-Eide D., and Ohlsson C. Effects of cortisol on the expression of interleukin-6 and interleukin-1 beta in human osteoblast-like cells. J Endocrinol 156 (1998) 107-114
44. Huber S.A., Sakkinen P., Conze D., Hardin N., and Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19 (1999) 2364-2367
45. Sukhai M., Yong A., Pak A., and Piquette-Miller M. Decreased expression of P-glycoprotein in Interleukin-1beta and interleukin-6 treated rat hepatocytes. Inflamm Res 50 (2001) 362-370
46. Schieffer B., Selle T., Hilfiker A., Hilfiker-Kleiner D., Grote K., Tietge U.J., et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110 (2004) 3493-3500
47. Batetta B., Dessi S., Putzolu M., Sanna F., Spano O., Mulas M.F., et al. MDR1 gene expression in normal and atherosclerotic human arteries. J Vasc Res 36 (1999) 261-271
48. Metherall J.E., Li H., and Waugh K. Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J Biol Chem 271 (1996) 2634-2640
49. Elhage R., Clamens S., Besnard S., Mallat Z., Tedgui A., Arnal J., et al. Involvement of interleukin-6 in atherosclerosis but not in the prevention of fatty streak formation by 17 beta-estradiol in apolipoprotein E-deficient mice. Atherosclerosis 156 (2001) 315-320
50. Ridker P.M., Cannon C.P., Morrow D., Rifai N., Rose L.M., McCabe C.H., et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-Reactive protein levels and outcomes after statin therapy. N Engl J Med 352 (2005) 20-28
51. Tedgui A., and Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 86 (2006) 515-581
52. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 12 (2006) 178-180